• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素受体介导的糖皮质激素受体辅助装载调节前列腺癌细胞中的转录反应。

Androgen receptor-mediated assisted loading of the glucocorticoid receptor modulates transcriptional responses in prostate cancer cells.

作者信息

Hiltunen Johannes, Helminen Laura, Aaltonen Niina, Launonen Kaisa-Mari, Laakso Hanna, Malinen Marjo, Niskanen Einari A, Palvimo Jorma J, Paakinaho Ville

机构信息

Institute of Biomedicine, University of Eastern Finland, FI-70211 Kuopio, Finland.

Department of Forestry and Environmental Engineering, South-Eastern Finland University of Applied Sciences, FI-45100 Kouvola, Finland.

出版信息

Genome Res. 2025 Aug 1;35(8):1717-1732. doi: 10.1101/gr.280224.124.

DOI:10.1101/gr.280224.124
PMID:40456604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12315708/
Abstract

Steroid receptors are involved in a wide array of cross talk mechanisms that regulate diverse biological processes, with significant implications in diseases, particularly in cancers. In prostate cancer, indirect cross talk between androgen receptor (AR) and glucocorticoid receptor NR3C1 (also known as GR) is well documented, wherein AR suppression by antiandrogen therapy leads to elevated GR levels, enabling GR to compensate for and replace AR signaling. However, the existence and impact of direct chromatin cross talk between AR and GR in prostate cancer have remained elusive. Here, our genome-wide investigations reveal that AR activation significantly expands GR chromatin binding. Mechanistically, AR induces remodeling of closed chromatin sites, facilitating GR binding to inaccessible sites. Importantly, coactivation of AR and GR results in distinct transcriptional responses at both the cell population and single-cell levels. Pathways affected by these transcriptional changes are generally associated with improved patient survival. Thus, the direct cross talk between AR and GR yields markedly different outcomes from the known role of GR in circumventing AR blockade by antiandrogens.

摘要

类固醇受体参与了一系列广泛的相互作用机制,这些机制调节着多种生物过程,对疾病尤其是癌症具有重要影响。在前列腺癌中,雄激素受体(AR)与糖皮质激素受体NR3C1(也称为GR)之间的间接相互作用已有充分记录,其中抗雄激素治疗对AR的抑制会导致GR水平升高,使GR能够补偿并取代AR信号传导。然而,前列腺癌中AR与GR之间直接的染色质相互作用的存在及其影响仍不清楚。在此,我们的全基因组研究表明,AR激活显著扩展了GR在染色质上的结合。从机制上讲,AR诱导封闭染色质位点的重塑,促进GR与难以接近的位点结合。重要的是,AR和GR的共同激活在细胞群体和单细胞水平上都导致了不同的转录反应。受这些转录变化影响的通路通常与患者生存率提高相关。因此,AR与GR之间的直接相互作用产生的结果与GR在通过抗雄激素规避AR阻断中的已知作用明显不同。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/d2d2ddd93d5a/1717f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/f4d8036b4bed/1717f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/54bb39d6f650/1717f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/2c2a027f4c59/1717f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/a7292a5c566d/1717f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/d2d2ddd93d5a/1717f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/f4d8036b4bed/1717f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/54bb39d6f650/1717f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/2c2a027f4c59/1717f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/a7292a5c566d/1717f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f77/12315708/d2d2ddd93d5a/1717f05.jpg

相似文献

1
Androgen receptor-mediated assisted loading of the glucocorticoid receptor modulates transcriptional responses in prostate cancer cells.雄激素受体介导的糖皮质激素受体辅助装载调节前列腺癌细胞中的转录反应。
Genome Res. 2025 Aug 1;35(8):1717-1732. doi: 10.1101/gr.280224.124.
2
ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer.ONECUT2 在前列腺腺癌以及神经内分泌前列腺癌变异体中充当着谱系可塑性驱动因子。
Nucleic Acids Res. 2024 Jul 22;52(13):7740-7760. doi: 10.1093/nar/gkae547.
3
Androgen Receptor-Interacting Proteins in Prostate Cancer Development and Therapy Resistance.雄激素受体相互作用蛋白在前列腺癌发生和治疗抵抗中的作用。
Am J Pathol. 2024 Mar;194(3):324-334. doi: 10.1016/j.ajpath.2023.12.003. Epub 2023 Dec 15.
4
Androgen receptor and estrogen receptor variants in prostate and breast cancers.前列腺癌和乳腺癌中的雄激素受体与雌激素受体变体
J Steroid Biochem Mol Biol. 2024 Jul;241:106522. doi: 10.1016/j.jsbmb.2024.106522. Epub 2024 Apr 17.
5
The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance.长链非编码RNA lncZBTB10通过S-棕榈酰化促进雄激素受体功能,从而推动前列腺癌进展及阿比特龙耐药。
Br J Cancer. 2025 Apr;132(7):587-598. doi: 10.1038/s41416-025-02938-1. Epub 2025 Feb 16.
6
Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells.雄激素非依赖性前列腺癌细胞中AR和AR-V7的共价去稳定化降解剂
J Am Chem Soc. 2025 Jun 18;147(24):20512-20524. doi: 10.1021/jacs.5c02801. Epub 2025 Jun 9.
7
Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancer.RACGAP1 和 AR 之间的相互调节导致前列腺癌内分泌治疗耐药。
Cell Commun Signal. 2024 Jun 19;22(1):339. doi: 10.1186/s12964-024-01703-w.
8
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer.监测血浆衍生细胞外囊泡中的糖皮质激素受体作为前列腺癌中雄激素受体信号抑制耐药的标志物。
Cancer Res Commun. 2023 Dec 13;3(12):2531-2543. doi: 10.1158/2767-9764.CRC-23-0362.
9
Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors.二氢睾酮通过雄激素和糖皮质激素受体激活 STAT5 通路促进肾癌细胞增殖。
J Cancer Res Clin Oncol. 2019 Sep;145(9):2293-2301. doi: 10.1007/s00432-019-02993-1. Epub 2019 Aug 10.
10
ZFHX3 is integral to androgen/AR signaling involving protein association with AR in prostate cancer cells.锌指同源框蛋白3(ZFHX3)在前列腺癌细胞中与雄激素/雄激素受体(AR)信号传导相关,涉及蛋白质与AR的结合。
Sci Rep. 2025 Jul 1;15(1):20931. doi: 10.1038/s41598-025-05659-w.

本文引用的文献

1
Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate.典型雄激素反应元件基序是前列腺中的肿瘤抑制调节元件。
Nat Commun. 2024 Dec 13;15(1):10675. doi: 10.1038/s41467-024-53734-z.
2
Glucocorticoid receptor action in prostate cancer: the role of transcription factor crosstalk.糖皮质激素受体在前列腺癌中的作用:转录因子相互作用的角色。
Front Endocrinol (Lausanne). 2024 Jul 4;15:1437179. doi: 10.3389/fendo.2024.1437179. eCollection 2024.
3
Comparative cofactor screens show the influence of transactivation domains and core promoters on the mechanisms of transcription.
比较辅因子筛选显示了转录激活域和核心启动子对转录机制的影响。
Nat Genet. 2024 Jun;56(6):1181-1192. doi: 10.1038/s41588-024-01749-z. Epub 2024 May 20.
4
Transient loss of Polycomb components induces an epigenetic cancer fate.短暂丧失多梳成分会诱导表观遗传致癌命运。
Nature. 2024 May;629(8012):688-696. doi: 10.1038/s41586-024-07328-w. Epub 2024 Apr 24.
5
The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression.雌激素信号通路重编程前列腺癌细胞代谢,支持增殖和疾病进展。
J Clin Invest. 2024 Apr 16;134(11):e170809. doi: 10.1172/JCI170809.
6
Enhancer switching in cell lineage priming is linked to eRNA, Brg1's AT-hook, and SWI/SNF recruitment.细胞谱系启动中的增强子切换与 eRNA、Brg1 的 AT 钩和 SWI/SNF 募集有关。
Mol Cell. 2024 May 16;84(10):1855-1869.e5. doi: 10.1016/j.molcel.2024.03.013. Epub 2024 Apr 8.
7
EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells.EP300/CREBBP 乙酰转移酶抑制物可抑制前列腺癌细胞中甾体受体和 FOXA1 信号通路。
Cell Mol Life Sci. 2024 Apr 2;81(1):160. doi: 10.1007/s00018-024-05209-z.
8
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.一项在转移性去势抵抗性前列腺癌患者中进行的恩扎鲁胺联合选择性糖皮质激素受体调节剂瑞卡帕尼的 I 期临床试验。
Clin Cancer Res. 2024 Jun 3;30(11):2384-2392. doi: 10.1158/1078-0432.CCR-23-3636.
9
Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.染色质可及性和先驱因子 FOXA1 限制前列腺癌中糖皮质激素受体的作用。
Nucleic Acids Res. 2024 Jan 25;52(2):625-642. doi: 10.1093/nar/gkad1126.
10
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.腔面型乳腺癌的特征是糖皮质激素受体活性丧失。
EMBO Mol Med. 2023 Dec 7;15(12):e17737. doi: 10.15252/emmm.202317737. Epub 2023 Oct 30.